Abstract: Viral gastroenteritis is an important cause of morbidity and mortality worldwide, being particularly severe for children under the age of five. The most common viral agents of gastroenteritis are noroviruses, rotaviruses, sapoviruses, astroviruses and adenoviruses, however, no specific antiviral treatment exists today against any of these pathogens. We here discuss the feasibility of developing a broad-spectrum antiviral treatment against these diarrhea-causing viruses. This review focuses on the viral polymerase as an antiviral target, as this is the most conserved viral protein among the diverse viral families to which these viruses belong to. We describe the functional and structural similarities of the different viral polymerases, the antiviral effect of reported polymerase inhibitors and highlight common features that might be exploited in an attempt of designing such pan-polymerase inhibitor.
Introduction: The Need and the Concept of Antiviral Treatment for Viral Diarrhea
Acute gastroenteritis (AGE) occurs worldwide and is an important health issue that affects all age groups. Human rotaviruses (HRV), dsRNA viruses belonging to the Reoviridae family, are the most important cause of viral AGE in children <5 years, annually resulting in 215,000 deaths [1] . After the introduction of two rotavirus vaccines, human noroviruses (HNoV), (+)ssRNA viruses belonging to the Caliciviridae family, have been gaining impact in this age group, becoming in fact the most common viral agent of AGE in all age groups, resulting in 200,000 deaths per year [2] . Other human diarrhea-causing viruses such as astroviruses (HAstV, Astroviridae, (+)ssRNA), sapoviruses (HSaV, Caliciviridae, (+)ssRNA) and adenoviruses type 40 and 41 (HAdV, Adenoviridae, dsDNA) are common agents of AGE in young children, causing more moderate disease and being less prevalent than rota-and noroviruses. Infection with these viruses occurs via the fecal-oral route, by ingestion of contaminated food or water and by person-to-person contact. Large outbreaks occur frequently, disturbing the functioning of health institutions, long-term care facilities and other semi-closed environments [3] .
AGE manifests suddenly, with vomiting and watery non-bloody diarrhea being the most common symptoms. Differentiating the causative agent based on symptoms alone is unfeasible, thus specific diagnostic tests are required. Although AGE is normally self-limiting, it can be debilitating, with
The Viral Polymerase as an Antiviral Target
As major diarrhea-causing viruses belong to different viral families, their viral polymerases show substantial differences in functionalities and interactions with other factors to exert their function. Nonetheless, the viral polymerase represents the most conserved target among diverse viral families, as it maintains the same overall structure and functional motifs, despite significant amino-acid sequence variations [9, 10] . The viral polymerase is an excellent antiviral target, as proven by the successful antivirals developed against herpesviruses (e.g., acyclovir), HCV (e.g., sofosbuvir), HIV (various nucleoside and non-nucleoside reverse transcriptase inhibitors). Also for RSV (Lumicitabine or ALS-8176) and Ebola virus (Remdesivir or GS-5734) potent nucleoside polymerase inhibitors are in development [11] . This protein therefore represents the most suitable choice to identify broad-spectrum antiviral agents that can block the replication of all, or most, diarrhea-inducing viruses at the same time. 
Functional and Structural Comparison of the Viral Polymerase in Diarrhea-Causing Viruses
The viral RNA-dependent RNA-polymerase (RdRp) of noro-and sapoviruses [12] , which belong to two genera within the Caliciviridae, replicates their (+)ssRNA genome by initiating RNA synthesis according to two different modes, de novo and primed by VPg (viral protein genome-linked) [13] . Sapovirus and norovirus RdRps share high structural analogies, with a sequence similarity of 34% [14] . A crystal structure is available for HSaV in the apo form [14] , while several crystal structures are available for human and murine norovirus (MNV) RdRp, including the apo form and multiple complexes with ion cofactors, RNA elements, nucleotide analogues and non-nucleoside inhibitors [9, [15] [16] [17] [18] [19] [20] . The structures of HNoV and HSaV RdRps and their superimposition are illustrated in Figure 1a- 
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The Ramachandran plot (data not shown) confirmed that all residues of the catalytic site in our model are in the allowed region for their backbone dihedral angles, indicating its reliability to assess in silico potential nucleoside inhibitors targeting the active site. Such models cannot be used with confidence to evaluate allosteric sites. Differently from the other diarrhea-causing viruses, HAdVs have a linear dsDNA genome, replicated by the viral DNA polymerase (HAdV Pol) according to a protein-primed mechanism [40] . HAdV Pol belongs to the B-family of DNA polymerases, and it contains an exonuclease domain responsible for its proofreading function. Differently from RNA polymerases, HAdV Pol also presents two extra subdomains, TPR1 and TPR2, whose function is not completely understood. HAdV Pol forms a replication complex with viral and cellular factors to produce viral genome duplexes [41] , with a mechanism similar to the DNA replication of bacteriophages, including the Bacillus subtilis bacteriophage f29 [42] . While a crystal structure is not available for HAdV Pol, structural data is available for the bacteriophage f29 DNA polymerase [43] , and we used its ternary complex with a DNA primer and substrate (PDB 2PYL) to prepare a homology model for HAdV Pol from the sequence of HAdV serotype 40 (UniProtKB entry P48311), using MOE2018.10 [38] . The two protein sequences were manually aligned to match reported functional alignments (Figure 4a ) [44] , and the final model for HAdV Pol is shown in Figure 4b . As with our HAstV RdRp model, also this one can be used to evaluate the binding of nucleoside inhibitors, but not to evaluate allosteric ones. Differently from the other diarrhea-causing viruses, HAdVs have a linear dsDNA genome, replicated by the viral DNA polymerase (HAdV Pol) according to a protein-primed mechanism [40] . HAdV Pol belongs to the B-family of DNA polymerases, and it contains an exonuclease domain responsible for its proofreading function. Differently from RNA polymerases, HAdV Pol also presents two extra subdomains, TPR1 and TPR2, whose function is not completely understood. HAdV Pol forms a replication complex with viral and cellular factors to produce viral genome duplexes [41] , with a mechanism similar to the DNA replication of bacteriophages, including the Bacillus subtilis bacteriophage f29 [42] . While a crystal structure is not available for HAdV Pol, structural data is available for the bacteriophage f29 DNA polymerase [43] , and we used its ternary complex with a DNA primer and substrate (PDB 2PYL) to prepare a homology model for HAdV Pol from the sequence of HAdV serotype 40 (UniProtKB entry P48311), using MOE2018.10 [38] . The two protein sequences were manually aligned to match reported functional alignments (Figure 4a ) [44] , and the final model for HAdV Pol is shown in Figure 4b . As with our HAstV RdRp model, also this one can be used to evaluate the binding of nucleoside inhibitors, but not to evaluate allosteric ones. While it remains challenging to identify a broad-spectrum agent that targets all five polymerases, some overall structural similarities might be exploited to attempt to design such a panpolymerase inhibitor. Although identifying an allosteric site common to all polymerases appears unfeasible, the enzyme active site, in particular the incoming nucleotide subsite, is relatively conserved across the different viruses ( Figure 5 ). This represents a promising starting point to design broad-spectrum nucleoside inhibitors. While it remains challenging to identify a broad-spectrum agent that targets all five polymerases, some overall structural similarities might be exploited to attempt to design such a pan-polymerase inhibitor. Although identifying an allosteric site common to all polymerases appears unfeasible, the enzyme active site, in particular the incoming nucleotide subsite, is relatively conserved across the different viruses ( Figure 5 ). This represents a promising starting point to design broad-spectrum nucleoside inhibitors. 
Known Polymerase Inhibitors of Diarrhea-Causing Viruses
Different polymerase inhibitors have been found to be active against human noro-, sapo-, rotaand adenoviruses. Until now, no replication inhibitors have been reported for HAstV. The only explored antiviral agent, ribavirin, shows no clear efficacy in case reports [45, 46] .
Nucleoside Inhibitors
Nucleoside analogues are generally phosphorylated by cellular enzymes to their triphosphate active form, which is incorporated by the viral polymerase in the growing nucleic acid strand, leading to chain termination or viral mutagenesis [47, 48] . The nucleoside CMX521 (Figure 6 ) is the first drug candidate to be moved to phase I trials for the treatment of norovirus infections. It is active against multiple norovirus genotypes and effective in MNV-infected mice treated orally [49] . Ribavirin (RBV) has shown some inhibitory effect against NoV in vitro [50] , but failed to demonstrate a clear benefit to patients [7] . Favipiravir (T-705), marketed in Japan to treat influenza [51] , and its analogue T-1105 inhibit MNV replication in cells [52, 53] , and showed variable efficacy in mouse models [54, 55] . Other nucleoside analogues active against MNV and HNoV replication are 2'-C-methyl-cytidine (2CMC) [56, 57] , and its fluorinated analogue 2'-fluoro-2'-C-methyl-cytidine (2'-F-2CMC), the parent nucleoside of mericitabine [58] . Moreover, 2CMC and the 7-deaza-2'-C-methylated analogue of adenosine (7DMA) also inhibit the replication of sapovirus and rotavirus [59] , hinting that the proposed broad-spectrum inhibition of multiple viral polymerases is feasible. Finally, 5-nitro cytidine triphosphate (NCT), whose parent nucleoside inhibits poliovirus and coxsackievirus B3 [60] , and 2'-amino cytidine triphosphate (ACT) have been co-crystallized with the HNoV RdRp [15, 16] . 
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The triphosphate forms of the suggested nucleoside analogues have been analyzed with docking simulations [74] on the NTP binding pocket of the HNoV RdRp, as representative for RNA viruses, and on the active site of our model for HAdV Pol. As exemplified for one potential structure (Figure 9) , docking results confirm the potential of these analogues to fit the active pocket of both polymerases. The triphosphate forms of the suggested nucleoside analogues have been analyzed with docking simulations [74] on the NTP binding pocket of the HNoV RdRp, as representative for RNA viruses, and on the active site of our model for HAdV Pol. As exemplified for one potential structure ( Figure  9 ), docking results confirm the potential of these analogues to fit the active pocket of both polymerases.
Non-Nucleoside Inhibitors
To date, non-nucleoside inhibitors targeting the viral polymerase have been reported only for norovirus (Figure 10 ), and some have been co-crystallized with the enzyme, allowing the identification of three allosteric sites in NoV RdRp. Suramine and NF023 bind the NTP access pathway between fingers and thumb sub-domains [19] , naphthalene di-sulfonate NAF2 binds to a sub-pocket of the thumb domain [24] , while PPNDS binds to a second sub-region of the thumb domain [20] . These compounds have no activity against the viral replication in cells, possibly due to poor cell permeability [19] , while the HNoV RdRp inhibitor NCI02 inhibits both HNoV and MNV replication [75] , and NIC12, a weak inhibitor of poliovirus polymerase [76] , weakly inhibits MNV replication in cells [75] . Different allosteric inhibitors of HCV polymerase were recently evaluated as inhibitors of Caliciviridae RdRps [77] : JTK-109, TMC-647055 and Beclabuvir (Figure 10 ) inhibited six Caliciviridae RdRps, spanning Norovirus, Sapovirus and Lagovirus. JTK-109 also inhibited MNV replication in cell-based assays, providing a potential starting point to develop pan-RdRp inhibitors. 
Challenges and Potential Limitations to This Approach
In Vitro and In Vivo Replication Systems Available for Diarrhea-Causing Viruses
One of the main reasons for the lack of antiviral therapies against viral AGE, is the lack of suitable cell culture systems and/or animal models for the majority of these viruses. The HNoV is not easily cultivated in vitro or in vivo, therefore most antiviral research is being performed on the MNV or the HNoV GI replicon. Only recently it was reported that HNoV can replicate in the human B-cell line BJAB and in stem-cell-derived enteroids [78, 79] . These models were a first breakthrough in cultivating the HNoV but further optimization would facilitate their use in drug discovery campaigns. For HSaV there is no in vitro or in vivo replication system available. The porcine SaV Cowden strain can infect gnotobiotic pigs and porcine kidney cells in the presence of bile acids [80, 81] . Multiple strains of rotaviruses can be cultivated in vitro in the presence of trypsin; in vivo models to study rotavirus infections are rather limited [82] [83] [84] . HAdVs type 40 and 41 have limited ability to replicate in cells, when compared to other adenovirus subtypes, plus animal models are lacking [85] . Most HAstV genotypes grow in cell culture [86] but there is no small animal model available. A murine astrovirus model in immunodeficient mice has been reported [87] , but the most widely used in vivo model are turkey poults, which are infected with the turkey astrovirus [88] .
One advantage of developing polymerase-targeting inhibitors is the availability of enzymatic assays which allow the initial optimization of small molecule inhibitors, which can go into cellular assays at a later stage. These are available for multiple norovirus genotypes, for sapovirus and adenoviruses, but not for astroviruses [19, 89] . In the case of rotavirus, polymerase activity can be assessed using purified viroplasms containing the active polymerase-capping enzyme complex VP1-VP3 [59] . Nonetheless, the limited availability of models is a limitation for drug discovery efforts, also because these would help to further understand the viral life cycles thus providing important insights for the development of antiviral therapy.
Antiviral Drug Resistance
Viral replication usually has a high error rate, causing the generation of resistant mutants able to evade a given treatment, in particular if administered long-term. This has been observed with early anti-HIV reverse transcriptase inhibitors, but later overcome with combination therapies of drugs belonging to different classes, with high genetic barrier to resistance, i.e., requiring multiple mutations for the virus to become resistant [90] . Also for HCV, multi-drug treatment regimens (most of which now include sofosbuvir) are characterized by a high barrier to resistance [91] , allowing the suppression of most HCV genotypes [92] .
Although all direct-acting antiviral agents can lead to resistance, this issue would have a different impact in the case of the acute infections, as gastroenteritis mostly is. Treatment of acute infections aims to reduce virus replication enough to allow the immune system to clear the virus, and is therefore of short duration [93] . The incidence and clinical impact of resistance development would therefore be different and less likely to occur than for chronic infections.
In addition, resistant viral strains are usually less virulent than the wild type [94] , and acute viral infections still resolve in a self-limited manner. Even when treating prolonged/chronic norovirus infections, the treatment course(s) would be expected to be short, potentially rendering the issue of resistance less problematic in this context.
Mitochondrial Toxicity
Several drugs cause mitochondrial toxicity as a side effect, potentially leading to tissue damage and organ failure. The main risk of mitochondrial toxicity for antivirals acting on the viral polymerase or reverse-transcriptase is due to inhibition of the mitochondrial γDNA-polymerase [95] or RNA-polymerase POLRMT [96] . This side-effect on the γDNA-polymerase is relevant for the anti-HIV nucleoside reverse-transcriptase inhibitors zalzitabine (ddC), didanosine (ddI), stavudine (d4T), zidovudine (AZT), lamivudine (3TC), abacavir (ABC) and tenofovir (TFD) [97, 98] . Similarly, different antiviral ribonucleoside analogs show toxic effects due to their affinity for POLRMT. In particular, valopicitabine, an ester prodrug of 2CMC in phase 2 clinical trials for HCV, was not advanced further due to gastrointestinal toxicity [99] , while the triphosphate active forms of 2'-C-methyl nucleosides 2CMC, 2CMA and 2CMG inhibit POLRMT by chain termination [100] , indicating a potential underlying issue for the development of any 2'-C-methylated nucleoside into a drug. However, the triphosphate form of 2CMU (uridine) does not impact POLRMT function [96] , while sofosbuvir, which combines a 2'-C-methyl feature with a 2'-fluorine substitution on the sugar, does not cause any mitochondrial inhibition [101] . General evidence appears to indicate that 2'-monosusbtitutions, along with 4'-monosubstitutions, on the sugar of antiviral ribonucleosides do not provide selectivity for the viral polymerase over POLRMT, with the associated mitochondrial toxicity mainly due to the core nucleoside rather than the cleaved prodrug moieties [97] . Nonetheless, structure-activity relationships for mitochondrial toxicity remain unpredictable, and this off-target effect can potentially be avoided with tuned modifications at both the sugar and the nucleobase level of selected nucleoside analogues. Potential mitochondrial toxicity should thus be carefully evaluated for each single nucleoside analogue of interest, possibly following a recently developed screening method which combines together multiple biochemical and cellular assays to assess this undesired effect [97] .
Concluding Remarks
Almost one hundred antivirals have been marketed since 1963, however mostly to treat one specific human viral disease [4] . Given the diversity of human viral pathogens, there is the need to focus on broad-spectrum inhibitors against viral families or even all RNA or DNA viruses. We here explored this approach for rota-, noro-, sapo-, astro-, and adenovirus. In this review, we have emphasized the viral polymerase by studying the functional and structural similarities between the selected polymerases, as in our perspective this offers a starting point for broad-spectrum therapy against diarrhea-causing viruses. The next step would be an in silico structure-based screening of nucleoside and non-nucleoside small-molecules, using a series of molecular docking simulations on the crystal structures or homology models of the five polymerase discussed. This strategy would allow the identification of chemical scaffolds with good predicted affinity for all proteins at the same time, while their subsequent assessment in enzymatic inhibition assays would provide potential broad-spectrum hits for further optimization. 
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